Medication overuse-headache

Read more about the research's members, background, current projects and collaboration.​


Rigmor Jensen, Ninett Louise Find, Lars Bendtsen, Signe Bruun Munksgaard, Maria Westergaard, Rossana Terlizzi.


Medication-overuse headache (MOH) is a daily or almost daily type of headache that usually results from the chronification of primary forms, such as migraine or tension-type headache, as a consequence of the progressive increase in the intake of symptomatic drugs. Limited amount of data exists on the burden of MOH, even in developed countries, but there is general agreement that the disease represents one of the most disabling disorders, which markedly deteriorates the quality of life of patients, exposing them to the risks of side-effects and co-morbid conditions. Our knowledge on the mechanisms leading to MOH is limited, and there are virtually no data on how these severely patients are treated optimally. Thus, there is an urgent need for studies investigating the pathophysiology and treatment possibilities of MOH.

​Current projects

An EU-founded multi-centre study (COMO-ESTAS) investigating the benefit of electronic headache diaries during detoxification of MOH has been finalized and results are underway for publication. The first reports demonstrate a highly significant reduction in headache frequency, more than 2 thirds reverse from chronic to episodic headache. The depression and anxiety-scores are markedly reduced by mere detoxification and indicate that these comorbidities are a function of severe headache and not causative to the pain. A new project testing the efficacy of 2 different detoxification programmes and the potential biomarkers for relapse in close collaboration with University of Bologna is drafted.


C. Tassorelli, Fondazione Istituto Neurologico Casimiro Mondino, Italy. M. Lainez, Fundación de la Comunidad Valenciana para la Investigación Biomédica del Hospital Clínico Universitario De Valencia, Spain. Z. Katsarava, universitaetsklinikum Essen, Germany. R. Fadic, Pontificia Universidad Catolica de Chile, Santiago, Chile. A. Stoppini, Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia, Buenos Aires, Argentina. Lars ​Thorbjørn, Klinisk Biokemisk afdeling, Glostrup Hospital. Dr Csaba Ertsey, Department of Neurology, Semmelweis University, Budapest, Hungary, Pietro Cortelli, Department of ​Neurology, University of Bologna.

Responsible editor